Should I buy or sell Cardiff Oncology stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRDF shares. View CRDF analyst ratings or view top-rated stocks .

What is Cardiff Oncology's stock price target for 2024?

2 equities research analysts have issued 12 month target prices for Cardiff Oncology's stock. Their CRDF share price targets range from $7.00 to $14.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 140.3% from the stock's current price. View analysts price targets for CRDF or view top-rated stocks among Wall Street analysts .

How have CRDF shares performed in 2024?

Cardiff Oncology's stock was trading at $1.48 on January 1st, 2024. Since then, CRDF stock has increased by 195.3% and is now trading at $4.37. View the best growth stocks for 2024 here .

Are investors shorting Cardiff Oncology?

Cardiff Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,410,000 shares, an increase of 21.4% from the March 15th total of 2,810,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 2.0 days. View Cardiff Oncology's Short Interest .

When is Cardiff Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRDF earnings forecast .

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The firm earned $0.16 million during the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative net margin of 8,492.01% and a negative trailing twelve-month return on equity of 50.13%.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE) , Livongo Health (LVGO) , Co-Diagnostics (CODX) , Novavax (NVAX) , Fortress Biotech (FBIO) , Maxar Technologies (MAXR) , Ontrak (OTRK) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA) .

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRDF

Cardiff Oncology (CRDF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CRDF Stock Alerts

$4.37

-0.13 (-2.89%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.26
▼
$4.48
50-Day Range: $1.66
▼
$5.91
52-Week Range: $0.94
▼
$6.42

Volume: 827,721 shs
Average Volume: 1.13 million shs
Market Capitalization: $195.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Get Cardiff Oncology alerts:

Cardiff Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 140.3% Upside
$10.50 Price Target
Short Interest: Bearish
7.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.14
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.98) to ($1.05) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

Medical Sector

743rd out of 918 stocks

Biological Products, Except Diagnostic Industry

124th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Cardiff Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cardiff Oncology has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.63% of the outstanding shares of Cardiff Oncology have been sold short.
Short Interest Ratio / Days to Cover
Cardiff Oncology has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cardiff Oncology has recently increased by 21.35%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cardiff Oncology does not currently pay a dividend.
Dividend Growth
Cardiff Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRDF.

3.4

News and Social Media Coverage

News Sentiment
Cardiff Oncology has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Cardiff Oncology this week, compared to 1 article on an average week.
Search Interest
37 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cardiff Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.30% of the stock of Cardiff Oncology is held by insiders.
Percentage Held by Institutions
Only 16.29% of the stock of Cardiff Oncology is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cardiff Oncology are expected to decrease in the coming year, from ($0.98) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cardiff Oncology is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cardiff Oncology is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cardiff Oncology has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Cardiff Oncology Stock (NASDAQ:CRDF)

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRDF Stock News Headlines

April 13, 2024 | americanbankingnews.com

William Blair Comments on Cardiff Oncology, Inc.'s Q1 2025 Earnings (NASDAQ:CRDF)

April 9, 2024 | investorplace.com

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 8, 2024 | globenewswire.com

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

March 27, 2024 | msn.com

bluebird bio falls as accounting errors force restatements

March 21, 2024 | investorplace.com

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5

March 16, 2024 | finance.yahoo.com

REGN Mar 2024 1010.000 put

March 16, 2024 | finance.yahoo.com

REGN Mar 2024 982.500 call

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 15, 2024 | finance.yahoo.com

CRDF Apr 2024 2.500 call

March 15, 2024 | finance.yahoo.com

CRDF Nov 2024 10.000 put

March 15, 2024 | finance.yahoo.com

CRDF Apr 2024 5.000 call

March 14, 2024 | finance.yahoo.com

REGN Mar 2024 992.500 call

March 8, 2024 | seekingalpha.com

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

March 6, 2024 | globenewswire.com

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

March 3, 2024 | finance.yahoo.com

Cardiff Oncology Full Year 2023 Earnings: Beats Expectations

March 2, 2024 | seekingalpha.com

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Call Transcript

March 1, 2024 | msn.com

Nasdaq Surges 100 Points; ISM Manufacturing PMI Falls In February

March 1, 2024 | msn.com

Small Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock Soars

March 1, 2024 | finance.yahoo.com

Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results

March 1, 2024 | uk.finance.yahoo.com

Q4 2023 Cardiff Oncology Inc Earnings Call

March 1, 2024 | finanznachrichten.de

Cardiff Oncology, Inc.: Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

March 1, 2024 | markets.businessinsider.com

TD Cowen Sticks to Their Buy Rating for Cardiff Oncology (CRDF)

February 29, 2024 | globenewswire.com

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

February 29, 2024 | globenewswire.com

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

February 29, 2024 | globenewswire.com

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

See More Headlines

Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CRDF
CUSIP: N/A
CIK: 1213037
Web: cardiffoncology.com
Phone: (858) 952-7570
Fax: N/A
Employees: 31
Year Founded: 1999

Price Target and Rating

Average Stock Price Target: $10.50
High Stock Price Target: $14.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +140.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,440,000.00
Net Margins: -8,492.01%
Pretax Margin: -8,492.01%
Return on Equity: -50.13%
Return on Assets: -44.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.41
Quick Ratio: 7.41

Sales & Book Value

Annual Sales: $490,000.00
Price / Sales: 398.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.56 per share
Price / Book: 2.80

Miscellaneous

Outstanding Shares: 44,680,000
Free Float: 41,862,000
Market Cap: $195.25 million
Optionable: Optionable
Beta: 1.94

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Mark Erlander Ph.D. (Age 64)
CEO & Director
Comp: $2.43M
Mr. James E. Levine (Age 53)
Chief Financial Officer
Comp: $1.57M
Dr. Tod Smeal Ph.D. (Age 59)
Chief Scientific Officer?
Comp: $2.69M
Ms. Elizabeth Anderson
VP of Finance & Administration
Ms. Brigitte Lindsay
Senior Vice President of Finance
Mr. Charles Monahan R.Ph.
Senior VP of Regulatory Affairs
Dr. Fairooz Kabbinavar FACP (Age 66)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRDF Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings or view top-rated stocks.
What is Cardiff Oncology's stock price target for 2024?: 2 equities research analysts have issued 12 month target prices for Cardiff Oncology's stock. Their CRDF share price targets range from $7.00 to $14.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 140.3% from the stock's current price.
View analysts price targets for CRDF or view top-rated stocks among Wall Street analysts.
How have CRDF shares performed in 2024?: Cardiff Oncology's stock was trading at $1.48 on January 1st, 2024. Since then, CRDF stock has increased by 195.3% and is now trading at $4.37.
View the best growth stocks for 2024 here.
Are investors shorting Cardiff Oncology?: Cardiff Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,410,000 shares, an increase of 21.4% from the March 15th total of 2,810,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 2.0 days.
View Cardiff Oncology's Short Interest.

When is Cardiff Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRDF earnings forecast.
How were Cardiff Oncology's earnings last quarter?: Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The firm earned $0.16 million during the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative net margin of 8,492.01% and a negative trailing twelve-month return on equity of 50.13%.
What other stocks do shareholders of Cardiff Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).
How do I buy shares of Cardiff Oncology?: Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRDF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cardiff Oncology (CRDF) Stock Price, News & Analysis

Cardiff Oncology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cardiff Oncology Stock (NASDAQ:CRDF)

CRDF Stock Price History

CRDF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

CRDF Stock Analysis - Frequently Asked Questions

Overall MarketRank^™